Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LDL-apheresis therapy.

Patrick M Moriarty1

  • 1Department of Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. pmoriart@kumc.edu

Current Treatment Options in Cardiovascular Medicine
|October 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein apheresis in the era of new lipid-lowering therapies.

European heart journal·2026
Same author

Treatment of Clinically Diagnosed Alzheimer's Disease by External Counterpulsation A Randomized Clinical Trial.

American journal of Alzheimer's disease and other dementias·2026
Same author

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

European journal of preventive cardiology·2026
Same author

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.

Atherosclerosis·2026
Same author

Pelacarsen: Mechanism of action and Lp(a)-lowering effect.

Journal of clinical lipidology·2025
Same author

Correction to: Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.

Circulation·2025
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Low-density lipoprotein (LDL)-apheresis effectively lowers cholesterol and cardiovascular events in high-risk patients. This therapy also impacts other vascular markers, suggesting broader applications beyond hypercholesterolemia.

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Vascular Biology

Background:

  • Low-density lipoprotein (LDL)-apheresis is a proven treatment for severe hypercholesterolemia.
  • It significantly reduces plasma cholesterol (LDL reduction > 60%) and cardiovascular events.
  • Despite benefits, its use remains limited among eligible patients.

Purpose of the Study:

  • To highlight the efficacy of LDL-apheresis in uncontrolled hypercholesterolemia.
  • To explore the broader impact of apheresis on vascular disease markers.
  • To suggest potential new indications for LDL-apheresis.

Main Methods:

  • Review of existing literature on LDL-apheresis efficacy and mechanisms.
  • Analysis of apheresis's effects on plasma cholesterol levels.

Related Experiment Videos

  • Examination of apheresis's influence on inflammation, rheology, thrombosis, and fibrinolysis.

    • Main Results:

    • LDL-apheresis achieves acute and significant reductions in plasma LDL cholesterol.
    • The procedure is associated with a decrease in cardiovascular events in specific patient populations.
    • Apheresis modifies multiple vascular markers beyond lipid reduction.

    Conclusions:

    • LDL-apheresis is a valuable therapeutic option for patients with severe hypercholesterolemia resistant to standard treatments.
    • The impact of apheresis on various vascular markers suggests its potential utility in other disease states.
    • Further research is warranted to explore expanded applications of LDL-apheresis.